Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.
Buruli ulcer (BU) is a skin disease caused by Mycobacterium ulcerans infection that requires long-term antibiotic treatment and/or surgical excision. In this study, we investigated the therapeutic efficacy of the rifamycin derivative, rifalazil (RLZ) (also known as KRM-1648), in an advanced M. ulcer...
שמור ב:
| Principais autores: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science (PLoS)
2022-01-01
|
| סדרה: | PLoS ONE |
| גישה מקוונת: | https://doi.org/10.1371/journal.pone.0274742 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
